BCAT-IN-4 - An Overview
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage various intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis pa